Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ssCART-19 in relapsed or refractory CD19-positive acute B-lymphoblastic leukemia
CTR20241149Phase 2Active
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ssCART-19 in acute lymphoblastic leukemia (ALL), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.. Started Jun 2024; status: active.
02
Drugs
ssCART-19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20241149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241149.